



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Date: July 8, 2021

The Manager – Listing,
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex Bandra(E),
MUMBAI – 400 051.

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub: Clarification

Ref: Press release dated July 07, 2021, titled "legal update"

With reference to the above cited subject and your email dated July 8, 2021, we bring to your kind notice the following:

1	Brief details of litigation viz. name(s) of the opposing party, court/tribunal/agency where litigation is filed, brief details of dispute/litigation	FMC CORPORATION (FMC) filed at Delhi High Court on 2 nd November, 2019 vide CS(Comm) 611/2019 against our Company. Details of dispute - FMC has filed the suit against our Company seeking not to infringe their Indian Patent No. 201307 and 213332. The pronouncement of judgment on injunction application was passed orally in the open court through virtual hearing on 7 th July, 2021 by Hon'ble Justice C. Hari Shankar of High Court of Delhi. The judgement is yet to be uploaded on the Delhi High Court website. The Company will review all its options after the full Judgment is available.
2	Expected financial implications, if any, due to compensation, penalty, etc	NATCO has not yet launched the product CHLORANTRANILIPROLE (CTPR). Suit is valued at Rs.2,00,00,700/- (Rupees two crores seven hundred only) for the purpose of Court fees and jurisdiction.
3	Quantum of claims, if any	FMC reserve their right to claim damages.

This is for your information and records.

Thanking you,
Yours faithfully,
For NATCO Pharma Limited

M. Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)